PTC Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Good afternoon, everyone. My name is Gena Wang, I'm a mid-cap biotech analyst at Barclays. It is my great pleasure to introduce our next speaker, Stuart Peltz, Chief Executive Officer of PTCT; and also with us, we also have Marcio Souza, Chief Operating Officer, with us for the Q&A discussion.
Can you hear me? Great. Well, thank you -- thanks for the introduction and the invitation to be here. We're PTC Therapeutics, I'm Stuart Peltz. I will be talking about some forward-looking statements and I suggest that you look at our findings.
So I'll go through a little bit of 2018, I'll just put these up.
My goal here is to give us time to have questions and answers to things that you have, but I wanted to start out and just say, obviously 2018 was truly a transformational year for PTC. Our DMD franchise did quite well and was within guidance. We able to expand Translarna's availability by getting
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
